Laekna doses first subjects in Phase Ib/III breast cancer therapy trial
The trial will analyse the safety and efficacy of afuresertib plus fulvestrant combination in HR+/HER2- breast cancer patients.
News
Latest in
News
BMS’ Breyanzi offers durable response in Phase II lymphoma trial
Breyanzi had a manageable safety profile without any new safety signals reported.
NRx to halt analysis of Zyesami for critical Covid-19 due to futility
In the trial, a mortality rate of 37% was reported in the aviptadil arm versus 36% in the placebo arm.
Moleculin initiates subject dosing in Phase Ia Covid-19 treatment trial
The first-in-human trial will enrol nearly 80 participants to analyse WP1122 for treating Covid-19.
Harbour BioMed concludes first patient dosing in Phase I antibody trial
The HBM7008 antibody has crosslinking dependent specificity on tumours and potent immune modulation activity.
Oncotelic to commence Phase II mesothelioma combination therapy trial
The single-arm Simon's two stage trial will enrol up to 63 MPM patients across various US centres.
Valneva concludes lot-to-lot Phase III trial of chikungunya vaccine
The Phase III trial showed that three vaccine lots that were consecutively manufactured, elicited equivalent immune responses.
Codagenix doses first subject in Phase I intranasal Covid-19 vaccine trial
In previous trials, CoviLiv showed to stimulate strong immune responses and blocked nasal replication after a single dose.